A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

September 23, 2011

BMS Drug Boosts Hep C Cure Rates

Adding BMS-790052, an experimental hepatitis C drug being developed by Bristol-Myers Squibb, to pegylated interferon and ribavirin dramatically increased cure rates among first-time treatment takers with hepatitis C virus (HCV) genotype 1, according to a Phase IIa study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), held September 17 to September 20, in Chicago. Overall, 83 percent of people treated with 48 weeks of 10 or 60 milligrams (mg) BMS 790052 once-daily plus pegylated interferon and ribavirin achieved sustained virologic results, versus 25 percent of the group who received pegylated interferon and ribavirin plus placebo.

Some of the traditional indicators of treatment outcome did not always predict response to treatment. For example, all of the 36 people treated with BMS-790052 plus pegylated interferon and ribavirin had more than a 99 percent drop in their hepatitis C viral load after 12 weeks of treatment. This is known as an early virologic response, or EVR, and is usually an excellent indicator that treatment is working and should be continued. In the study reported at ICAAC, however, only 25 people with EVRs were ultimately cured.

Conversely, viral “blips”—when hepatitis C virus temporarily re-appears at a low level during or after treatment—did not always predict treatment failure. Of the seven patients who experienced blips, four were ultimately cured.

BMS-790052 belongs a class of drugs called NS5a replication complex inhibitors. Naturally occurring mutations known as polymorphisms are known to confer resistance to this class of drugs. But Stanislaus Pol, MD, of the Hôpital Cochin in Paris and his colleagues noted that these polymorphisms did not prevent people from being cured. Of the 13 study participants who had evidence of NS5a-associated polymorphisms before starting treatment, 10 were cured. However, evidence of resistance to BMS-790052 was found in all of the 11 people whose hep C virus returned during treatment or who relapsed afterward. 

BMS-790052 did not add to, or worsen, side effects from pegylated interferon and ribavirin. The investigators did not observe any increase in rash, liver-related side effects or laboratory abnormalities, with the addition of BMS 790052. However, the small size of this study—48 people total; 12 each in the 3 mg, 10 mg and 60 mg groups, and 12 in the placebo group—makes it is difficult to draw conclusions about side effects from BMS-790052; larger studies will be needed.

This trial was the first to test cure rates after triple therapy with an NS5a replication inhibitor. The investigators noted that the results support further studies of BMS-790052, in combination with other oral antiviral HCV drugs, with or without pegylated interferon and ribavirin.

Search: BMS-790052, Bristol-Myers Squibb, BMS, NS5a, replication complex inhibitors, RCIs, interferon, ribavirin, ICAAC, SVRs, EVRs


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    andais
    Red House
    West Virginia


    RyGuy00
    New York
    New York


    latinpozdallas
    Dallas
    Texas


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.